Clinical Outcomes of Intensive Versus Less Intensive First-Line Chemotherapy for Metastatic Colorectal Cancer

Figures & data

Figure 1. Patient flow chart.

aEGFR: Anti-epidermal growth factor receptor; BEV: Bevacizumab; Cape: Capecitabine; CAPIRI: Capecitabine and irinotecan; CAPOX: Capecitabine and oxaliplatin; CET: Cetuximab; CRC: Colorectal cancer; FOLFIRI: Fluorouracil, leucovorin and irinotecan; FOLFOX: Fluorouracil, leucovorin and oxaliplatin; FOLFOXIRI: Fluorouracil, leucovorin, oxaliplatin and irinotecan; FP: Fluoropyrimidine; 5-FU: Fluorouracil; IRI: Irinotecan; IRIS: S-1 and irinotecan; IT: Intensive therapy; JSCCR: Japanese Society for Cancer of the Colon and Rectum; LIT: Less intensive therapy; l-LV: l-Leucovorin; LV: Leucovorin; mCRC: Metastatic colorectal cancer; OX: Oxaliplatin; PANI: Panitumumab; S-1: Tegafur/gimeracil/oteracil potassium; SOX: S-1 and oxaliplatin; UFT: Tegafur/uracil.

Figure 2. Subgroup analysis of time to treatment failure between the intensive and less intensive therapy groups.

HR: Hazard ratio; IT: Intensive therapy; LIT: Less intensive therapy.

Table 1. Patient characteristics.

Figure 3. Time to treatment failure, time to first subsequent therapy and overall survival in the intensive and less intensive therapy groups.

Kaplan–Meier curves of (A) time to treatment failure, (B) time to first subsequent therapy and (C) overall survival.

IT: Intensive therapy; LIT: Less intensive therapy.

Figure 4. Time to treatment failure, time to first subsequent therapy and overall survival in the groups receiving treatment with and without molecularly targeted agents.

Kaplan-Meier curves of (A) time to treatment failure, (B) time to first subsequent therapy and (C) overall survival.

MTA: Molecularly targeted agent; w/: With; w/o: Without.

Figure 5. Subgroup analysis of time to treatment failure between the groups treated.

(A) With and without a molecularly targeted agent and (B) with and without bevacizumab.

BEV: Bevacizumab; HR: Hazard ratio; MTA: Molecularly targeted agent.

Figure 6. Time to treatment failure, time to first subsequent therapy and overall survival in the with and without bevacizumab groups.

Kaplan–Meier curves of (A) time to treatment failure, (B) time to first subsequent therapy and (C) overall survival.

BEV: Bevacizumab; w/: With; w/o: Without.

Data sharing statement

Data generated and/or analyzed during this study will not be shared due to concerns about data protection regulations in our country.